Encouraging results on Covid-19 vaccine trials by frontrunners in November have raised hopes that a first generation of coronavirus antidotes is likely to receive approval as soon as December end or early 2021. Ongoing late-stage human trials of mRNA vaccine candidates developed by Pfizer-BioNTech and Moderna Inc have pointed to efficacy rates as high as 95 per cent, sowing hopes across the world in the battle against the pandemic that has claimed 1.34 million lives and upended economies everywhere.
#Pfizer #Moderna #CoronavirusVaccine #OxfordAstraZeneca
SUBSCRIBE to HW News English Here ► [ Ссылка ]
Download the HW News Network free app available on Android and iOS: [ Ссылка ]
For NEWS and POLITICAL updates in English. Send us a ‘Hi’ on our Whatsapp Number - 9820918578
#HWNewsEnglish #HwLatestNews
For advertising related queries write to us at sales@hwnews.in
Connect With Us On:
→ Facebook: [ Ссылка ]
→ Twitter: [ Ссылка ]
For More Videos Visit Here:
[ Ссылка ]
